Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (March 2026)
13 slides from Revive Therapeutics's investor presentation, March 2026
Slide 1: A Specialty Life Sciences Company
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation MARCH 2026 OTC: FRANKFURT: RV V TF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: info@revivethera.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding o ur future
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Focused on the development of Bucillamine for infectious diseases, inflammatory disorders and medical countermeasures Robust patent portfolio covering methods and compositions © COPYRIGHT 2026. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
Slide 4: Strategy
STRATEGY Clinical development Target Markets Intellectual Property FDA Designations • Bucillamine • Infectious Diseases • Novel Uses • Orphan Drug • Nerve Agent Exposure • Medical • Formulations • Fast Track Countermeasures • Breakthrough • Rare Disorders Therapy © COPYRIGHT 2026. Revive Therapeutic
Slide 5: Intellectual Property Portfolio
INTELLECTUAL PROPERTY PORTFOLIO Title P ate nt S ta tus U se o f Bucilla mine in the Treatment of Infectious Dis eas es, Granted: Canadian Patent No. 3,172,170 (expires March 16, 2041) inclu ding COVID-19 Review: US 17/912,597, Japan 2022-556099 Compositions, Methods and Uses of Bucillamine in the T
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases and Medial Countermeasures Product Indication Stage of Development Regulatory Status Bucillamine Infectious Diseases Determining next steps Completed Phase 3 (Oral Tablet) COVID-19 and international opps Medical Defence R&D Canada – Research funded by Su
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Bucillamine potential for Bucillamine Revive’s clinical history Bucillamine scientific COVID-19 Safety Profile with Bucillamine rationale as an intervention for COVID-19 (see Appendix) • Potential treatment for reduction in • Well-known safety profile and prescribed •
Slide 8: Strategic Partners
STRATEGIC PARTNERS Bucillamine Bucillamine Chemical Warfare Formulation © COPYRIGHT 2026. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
Slide 9: Expected Milestones
EXPECTED MILESTONES Q1 Q2 2026 2026 • Results of Bucillamine for nerve • Further initiatives for Bucillamine agent exposure at DRDC with DRDC © COPYRIGHT 2026. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
Slide 10: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Arshi Kizilbash, M.D. • William Jackson Chief Financial Officer Medical Advisor, Co
Slide 11: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap RV V (CSE) | RV V T F (OTC) | 31R (Frankfurt) CAD $0.06 / $0.005 CAD ~ $25,000,000 Share Price Capital Structure CAD $0.06 (March 13, 2026) 418,564,269 common shares 35,320,334 stock options 63,317,263 warrants ($0.05 - $0.20) © COPYRIGHT 2026. Re
Slide 12: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at -risk populations, such as the elderly. 1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of effic
Slide 13: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitte d to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant dat
Revive Therapeutics — Investor Presentation (March 2026) on 6ix